๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca231 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC129 Novartis Pharmaceuticals113
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in California

5301 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Low Grade Upper Tract Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT07305818Graves Disease
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982Spinal Muscular Atrophy (SMA)
DrugARGX-119
argenx
Phase 2
60
Arkansas, California, Connecticut, Florida, Illinois, Iowa, Maryland, Massachusetts
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugPF-08653944
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Illinois, Michigan, Nebraska, New York, South Carolina, Texas
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686Obesity, Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
DrugsEmpasiprubart·Efgartigimod
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
NCT07135050Pitt Hopkins Syndrome
Mahzi Therapeutics
Phase 1/2
12
California, Colorado, Illinois
2025-12-19
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
DrugsEmpasiprubart·Efgartigimod
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Paclitaxel
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
NCT07287397Amyotrophic Lateral Sclerosis
Vector Y Therapeutics
Phase 1/2
12
Arizona, California, Florida, Massachusetts, New York, Pennsylvania
2025-12-19
Recruiting
The Effect of Kinisoquinโ„ข on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT06861088Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Quercis Pharma AG
Phase 3
480
California, Florida, Massachusetts
2025-12-19
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugBIC/FTC/TAF
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
85
California, Nevada, New Jersey, Texas
2025-12-18
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997Major Depressive Disorder
DrugIcalcaprant
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFirmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations
NCT07223177SpO2
Masimo Corporation
Not applicable
100
California
2025-12-17
Recruiting
A Study to Evaluate the Effects of a Prebiotic Soda on Glycemic Control in Adults
NCT07298135Blood Glucose Control
Olipop, PBC
Not applicable
224
California
2025-12-17
Active, closed
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
NCT07215468HIV -1 Infection
TaiMed Biologics Inc.
Phase 2
88
California, Florida, Nevada, New York, Texas
2025-12-16
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969Major Depressive Disorder (MDD)
DrugDT-101
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2025-12-16
Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New York, Washington
2025-12-16
Recruiting
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
NCT07505797Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
iSono Health, Inc.
Observational
800
California, Texas
2025-12-16
Recruiting
Secretome Treatment for Facial Rejuvenation
NCT07227883Facial Aging, Rejuvenation, Stem Cell, Stem Cell Banking
Acorn Biolabs Inc.
Phase EARLY_PHASE1
24
California
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
Accuracy Evaluation of the Owlet OSS 3.0-M1 Sensor in Toddlers and Preschoolers
NCT07321938Healthy
Owlet Baby Care, Inc.
Not applicable
90
California
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugPemetrexed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
A Study of a Thyroid Hormone Receptor Beta Isoform (THRฮฒ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138Metabolic Dysfunction-associated Steatohepatitis
DrugECC4703
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Maryland
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
NCT06887348Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Replimune, Inc.
Observational
50
California
2025-12-12
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, Florida, Georgia, Idaho, Louisiana, Minnesota
2025-12-12
Recruiting
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naรฏve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928Advanced Or Metastatic Merkel Cell Carcinoma
DrugsIFx-Hu2.0·Pembrolizumab
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
By invitation
Development and Application of Patient-Derived Models of Cancer
NCT07226180Cancer
Certis Oncology Solutions, Inc
Observational
40
California
2025-12-11
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC)
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
NCT06922539Small Cell Lung Cancer
DrugFenretinide
SciTech Development, Inc.
Phase 1
44
California, Michigan
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Bevacizumab
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-11
Active, closed
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
DrugsEzetimibe FDC·Obicetrapib
NewAmsterdam Pharma
Phase 3
300
Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland
2025-12-11
Recruiting
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT07214571Respiratory Syncytial Virus Infections
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
NCT07322094FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
TORL Biotherapeutics, LLC
Phase 1/2
60
California, Minnesota, New York, North Carolina
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Vinorelbine·Eribulin·Trastuzumab
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
Women's Hormonal and Metabolic Wellbeing Study
NCT07268404Metabolic Health
Daily Nouri
Not applicable
60
California
2025-12-10
Recruiting
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
NCT07290283Healthy Participants
AstraZeneca
Phase 1
176
California, Maryland
2025-12-10
Recruiting
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
NCT07089836Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum
American Laboratory Products Company
Observational
1,000
California, Florida, Texas
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Active, closed
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839COVID-19, SARS-COV-2 Infection
DrugBNT162b2 Vaccine
BioNTech SE
Phase 3
5,240
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
80
California, Florida, New Jersey, New York, Oregon, Tennessee
2025-12-09
Active, closed
ELIXIR MDTM Satisfaction Clinical Trial
NCT07676643Postoperative Complications, Plastic Surgery
Elixir MD Inc
Not applicable
148
California
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784Social Anxiety Disorder (SAD)
Newleos Therapeutics, Inc.
Phase 2
100
California, Florida, Massachusetts, Nevada, New York, Tennessee, Texas
2025-12-09
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
California, New Jersey, South Carolina, Texas
2025-12-09
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEYยฎ Kids)
NCT07107945Chronic Kidney Disease
DrugsJardiance·Empagliflozin
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Active, closed
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 1/2
104
California, Pennsylvania, Tennessee, Washington
2025-12-08
Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Recruiting
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
NCT07400965Demodex Blepharitis
Glaukos Corporation
Phase 2
250
California
2025-12-05
Recruiting
Immune Defense Protein Impact On Respiratory Immune Outcomes
NCT07431840Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Quantec Ltd
Not applicable
300
California
2025-12-05
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
160
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Ohio
2025-12-05
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
California, Texas, Utah
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Active, closed
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
NCT07310901Obese But Otherwise Healthy Participants
Corbus Pharmaceuticals Inc.
Phase 1
252
Alabama, Arizona, California, Florida, Kentucky, Nevada, New York, North Carolina
2025-12-04
Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
NCT06980948Chronic Neuropathic Pain
Sangamo Therapeutics
Phase 1/2
27
Arizona, Arkansas, California, Maryland, Massachusetts, New Hampshire, New York, North Carolina
2025-12-04
Recruiting
Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups
NCT06974773Endometriosis
Samphire Group, Inc.
Not applicable
120
California
2025-12-04
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
California, Florida, Illinois, Ohio, South Carolina, Texas, Wisconsin
2025-12-04
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York
2025-12-03
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New York, Tennessee, Texas
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Active, closed
Feasibility of Robotic Instrument Guidance System to Perform Safe Ultrasound-Guided Percutaneous Procedures During Routine Medical Procedures.
NCT07358351Percutaneous Access
Mendaera, Inc
Observational
46
California
2025-12-03
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341Metastatic Castration-resistant Prostate Cancer
DrugsValemetostat·Darolutamide
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Active, closed
Pulse Oximeter Accuracy During Stable Hypoxia Plateaus
NCT07408388Hypoxia
Nihon Kohden
Observational
48
California
2025-12-03
Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Focal Segmental Glomerulosclerosis
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Not yet open
The Impact of Qualia Gluthathione+ on Blood Glutathione Levels
NCT07221955Effects of Qualia Glutathione+ on Blood Glutathione Levels, Glutathione
Qualia Life Sciences
Not applicable
54
California
2025-12-02
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
DrugAbrocitinib
Pfizer
Phase 3
500
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
Active, closed
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900Obese, Obesity
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
267
California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas
2025-12-02
Not yet open
Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan
NCT07054593Healthy Subjects
Envivo Bio Inc
Phase 1
44
California
2025-12-01
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644Solid Tumors Harboring MET Amplification
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Recruiting
Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT07086521FSHD - Facioscapulohumeral Muscular Dystrophy
DrugULSC
Restem, LLC.
Phase 1
16
California
2025-12-01
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
Cardurion Pharmaceuticals, Inc.
Phase 2
12
California, North Carolina, Texas, Utah, Wisconsin
2025-12-01
Recruiting
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes
NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
DrugsPF-08634404·Ipilimumab
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Washington
2025-12-01
Active, closed
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
58
Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas
2025-12-01
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Rows per page Showing 901–1000 of 5301
Previous 8 9 10 11 12 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california?page=10

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,301 of those studies with a site in California.

How many clinical trials are recruiting in California?

2,761 of the 5,301 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 162 have not yet opened recruitment, 2,210 are active but closed to new participants, and 168 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.